Winslow Evans & Crocker Inc. Decreases Stake in Celgene Co. (NASDAQ:CELG)

Winslow Evans & Crocker Inc. reduced its stake in shares of Celgene Co. (NASDAQ:CELG) by 5.9% during the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 7,382 shares of the biopharmaceutical company’s stock after selling 466 shares during the period. Winslow Evans & Crocker Inc.’s holdings in Celgene were worth $686,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Archford Capital Strategies LLC raised its stake in shares of Celgene by 277.8% during the 1st quarter. Archford Capital Strategies LLC now owns 272 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 200 shares during the last quarter. Investors Research Corp acquired a new position in shares of Celgene during the 1st quarter worth $28,000. Liberty Wealth Management LLC acquired a new position in shares of Celgene during the 4th quarter worth $29,000. Weaver Consulting Group acquired a new position in shares of Celgene during the 1st quarter worth $29,000. Finally, Alera Investment Advisors LLC raised its stake in shares of Celgene by 109.9% during the 1st quarter. Alera Investment Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 167 shares during the last quarter. Institutional investors own 74.84% of the company’s stock.

CELG has been the subject of several research reports. William Blair initiated coverage on Q2 in a research note on Monday, April 1st. They set an “outperform” rating and a $69.71 price target for the company. Cantor Fitzgerald set a $11.00 price target on TAIWAN LIPOSOME/S and gave the stock a “buy” rating in a research note on Friday, April 5th. Cowen reaffirmed a “hold” rating and set a $102.00 price target on shares of Celgene in a research note on Tuesday. Sanford C. Bernstein reaffirmed a “sell” rating on shares of easyJet in a research note on Monday, April 1st. Finally, BidaskClub raised Xilinx from a “hold” rating to a “buy” rating in a research note on Wednesday, July 24th. Two analysts have rated the stock with a sell rating, sixteen have issued a hold rating and four have given a buy rating to the company. The company has an average rating of “Hold” and an average price target of $94.81.

CELG stock traded down $0.53 during trading on Tuesday, hitting $92.46. The stock had a trading volume of 1,386,680 shares, compared to its average volume of 3,638,123. The company has a 50 day moving average price of $93.67. Celgene Co. has a 1-year low of $58.59 and a 1-year high of $98.97. The company has a market capitalization of $65.42 billion, a PE ratio of 12.15, a price-to-earnings-growth ratio of 0.44 and a beta of 1.45. The company has a debt-to-equity ratio of 2.42, a quick ratio of 2.66 and a current ratio of 2.78.

Celgene Company Profile

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.

Recommended Story: What does an equal weight rating mean?

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.